High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial

Barkati, Maroie; Williams, Scott; Foroudi, Farshad; Tai, Keen Hun; Chander, Sarat; Dyk, Sylvia van; See, Andrew; Duchesne, Gillian

doi:10.1016/j.ijrobp.2010.09.006

Cited by 111 publications

(65 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Favorable intermediate risk patients were defined as those with a Gleason score of 3+4=7, cT2b disease, and 50% positive core biopsies (5). Low risk and favorable intermediate risk patients may be treated with HDR brachytherapy monotherapy (5,6,12,14). Unfavorable intermediate risk patients had a Gleason score of 4+3=7, cT2c disease, or >50% positive core biopsies (15,16).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Contreras

Wilder

Mellon

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…There has been only one prior report on HRQOL changes due to HDR brachytherapy monotherapy for prostate cancer (12). As a result, we studied HRQOL changes in this select group of patients.…”

Section: Introductionmentioning

confidence: 99%

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Contreras

Wilder

Mellon

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

“…По данным М. Barkati и соавт. [22], опубликованным в 2012 г., брахитерапию с высокой мощностью дозы можно рассматривать в качестве монотерапии для пациентов группы низкого и про-межуточного риска. Такое лечение в период с 2003 по 2008 г. было проведено 79 пациентам с РПЖ T2b-T2c стадии.…”

Section: брахитерапияunclassified

Radiation therapy for prostate cancer

Каприн¹,

Khmelevsky²,

Zubovskaya³

et al. 2016

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

“…Additional data are needed to understand the relationship between dose to sub-volumes of the prostate treated and its impact on urinary morbidity. Current literature is also hampered by the majority of studies reporting physician assessed toxicities, which are known to underestimate true toxicity relative to patient-reported outcomes (19).…”

Section: Urinary Toxicitymentioning

confidence: 99%

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

et al. 2015

View full text Add to dashboard Cite

PURPOSE: To assess the magnitude of dosimetric reductions of a focal and ultra-focal high-doserate (HDR) prostate brachytherapy treatment strategy relative to standard whole gland (WG) treatment. METHODS AND MATERIALS: HDR brachytherapy plans for five patients treated with WG HDR monotherapy were optimized to assess different treatment strategies. Plans were generated to treat the hemigland (HG), one-third gland (1/3G), and one-sixth gland (1/6G), as well as to assess treating the WG with a boost to one of those sub-volumes (WG þ HG, WG þ 1/3G, WG þ 1/6G). Dosimetric parameters analyzed included Target D90%, V100%, V150%, Bladder (B), Rectal (R), Urethral (U) D0.1, 1 and 2cc, Urethral V75%, and the V50% to the contralateral HG. Two-tailed t tests were used for comparison of means, and p-values less than 0.05 were considered statistically significant. RESULTS: Target objectives (D90 O 100% and V100 O 97%) were met in all cases. Significant organs at risk dose reductions were achieved for all approaches compared with WG plans. 1/6G vs WG plans resulted in the greatest reduction in dose with a mean bladder D2cc 24.7 vs 64.8%, rectal D2cc 32.8 vs 65.3%, urethral D1cc 52.1 vs 103.8%, and V75 14.5 vs 75% ( p ! 0.05 for all comparisons). CONCLUSION: Significant dose reductions to organs at risk can be achieved using HDR focal brachytherapy. The magnitude of the reductions achievable with treating progressively smaller sub-volumes suggests the potential to reduce morbidity, but the clinical impact on morbidity and tumor control remain to be investigated. Ó

show abstract

High-Dose-Rate Brachytherapy as a Monotherapy for Favorable-Risk Prostate Cancer: A Phase II Trial

Cited by 111 publications

References 25 publications

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Radiation therapy for prostate cancer

From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: A dosimetric analysis

Contact Info

Product

Resources

About